Baku Acharya

Researcher

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

8 h-index 86 pubs 196 cited

Research Areas

Links

ORCID Lab Website Research Group

OverviewAI-generated summary

Baku Acharya's research focuses on the development and characterization of small-molecule inhibitors for various oncogenic targets. His work has explored inhibitors for rearranged during transfection (RET) kinase, FLT3 in acute myeloid leukemia, and NEK2 in lymphoma. Acharya has also investigated novel therapeutic strategies, including dual RET/TRKA inhibitors and DNA-PKcs inhibitors with improved solubility.

His publications include work on kinase inhibitor macrocycles, targeting G-quadruplex structures in oncogene promoters, and patent reviews of RET kinase inhibitors. Acharya's research network includes extensive collaborations with Ying-Zhi Xu, Mason McCrury, Kennith Swafford, and Brendan Frett at the University of Arkansas for Medical Sciences, with whom he has co-authored numerous publications. He has an h-index of 8 and has published 90 total works, with 187 citations.

Metrics

h-index: 8
Publications: 86
Citations: 196

Selected Publications

Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)

2 citations DOI OpenAlex
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)

3 citations DOI OpenAlex
Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules (2023)

14 citations DOI OpenAlex
Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma (2023)

13 citations DOI OpenAlex
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present) (2022)

5 citations DOI OpenAlex
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms (2022)

26 citations DOI OpenAlex
Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group (2022)

5 citations DOI OpenAlex
Targeting TGF-β: Triumphs and Challenges (2022)

2 citations DOI OpenAlex
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development (2021)

35 citations DOI OpenAlex